RT Add-On May Boost Survival in Pediatric Hodgkin Lymphoma (CME/CE)
(MedPage Today) -- Researchers report drop in chemoradiotherapy use because of toxicity concerns (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 9, 2019 Category: Hematology Source Type: news

Chemo-Radiation Combo Tied to Higher Survival in Peds Hodgkin
WEDNESDAY, Jan. 9, 2019 -- Combined modality treatment (CMT) is associated with improved overall survival in pediatric patients with early-stage Hodgkin lymphoma (HL), according to a study published online Jan. 3 in JAMA Oncology. Sachin R. Jhawar,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 9, 2019 Category: Pharmaceuticals Source Type: news

Cerebellar Large B-cell Lymphoma: A Case Report Cerebellar Large B-cell Lymphoma: A Case Report
This case report reviews the diagnosis, pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers
Survivors have 14 - fold increased risk for developing a solid subsequent malignant neoplasm (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 7, 2019 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Pediatrics, Pharmacy, Pulmonology, Radiology, Journal, Source Type: news

Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers
MONDAY, Jan. 7, 2019 -- Survivors of childhood Hodgkin lymphoma (HL) remain at increased risk for developing subsequent malignant neoplasms (SMNs), according to research published online Dec. 17 in Cancer. Anna S. Holmqvist, M.D., Ph.D., from Lund... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2019 Category: Pharmaceuticals Source Type: news

Adding RT Tied to Better Survival in Pediatric Hodgkin Lymphoma
(MedPage Today) -- But use has dropped due to toxicity concerns (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 4, 2019 Category: Hematology Source Type: news

Nordstrom Co-president Blake Nordstrom dies at 58
The news comes less than a month after he announced he would undergo chemotherapy for lymphoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 3, 2019 Category: Biotechnology Authors: Coral Garnick Source Type: news

Nordstrom Co-president Blake Nordstrom dies at 58
The news comes less than a month after he announced he would undergo chemotherapy for lymphoma. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 3, 2019 Category: Pharmaceuticals Authors: Coral Garnick Source Type: news

Nordstrom Co-president Blake Nordstrom dies at 58
The news comes less than a month after he announced he would undergo chemotherapy for lymphoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 2, 2019 Category: Biotechnology Authors: Coral Garnick Source Type: news

Evaluating acalabrutinib in mantle cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news

Emotional video shows 13-year-old cancer patient finishing chemotherapy
George Harrison, from Doncaster, went through surgery and months of gruelling chemotherapy after being diagnosed with Hodgkin lymphoma in April when his parents thought he had food poisoning. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2018 Category: Consumer Health News Source Type: news

Synthetic turf pitches with rubber granulate infill: are there health risks for people playing sports on such pitches? - Pronk MEJ, Woutersen M, Herremans JMM.
The presence of carcinogenic substances in rubber granulate made from old car tyres raised concerns that the use of this granulate as infill on synthetic turf pitches may cause leukaemia and lymphoma in young football players and goalkeepers. Limitations i... (Source: SafetyLit)
Source: SafetyLit - December 25, 2018 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Childhood HL Survivors Face High Rates of Second Solid Cancers (CME/CE)
(MedPage Today) -- Quarter century study emphasizes need for individualizing screening in former Hodgkin lymphoma patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 21, 2018 Category: Hematology Source Type: news

Allergan pulls textured breast implants from the European market
Allergan (NYSE: AGN) has removed its textured breast implants from the market in Europe following a recall request from French regulators. France’s National Agency for the Safety of Medicines and Health Products said that it hasn’t “identified any immediate risk for the health of women carrying the implants,” and that it plans to convene an expert committee to discuss the matter in February next year. The New York Times reported this week that the implants were linked to an uncommon form of lymphoma that can arise years after the implant is placed. Allergan’s CE Mark in the E.U....
Source: Mass Device - December 19, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Implants Recalls Regulatory/Compliance Wall Street Beat Women's Health Allergan Source Type: news

Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer
The company ’ s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma. (Source: NYT Health)
Source: NYT Health - December 19, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Medical Devices Plastic Surgery Non-Hodgkin's Lymphoma France Allergan Inc Cancer Recalls and Bans of Products Europe Source Type: news

Lymphoma Still Top COD in Patients During Rituximab Era
Despite improved outcomes seen in the rituximab era, the leading cause of death in patients with follicular lymphoma during the first decade remains lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Untapped Radiotherapy Potential in Localized FL?
A study found follicular lymphoma patients staged with PET-CT and treated with radiotherapy appeared to have better outcomes than CT staging alone. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

High Solid Tumor Risk May Last a Lifetime for Childhood Lymphoma Survivors
(MedPage Today) -- 25-year study suggests need for individualized screening (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 19, 2018 Category: Hematology Source Type: news

After 40 Years, 26% of Pediatric HL Survivors Have a Solid Tumor After 40 Years, 26% of Pediatric HL Survivors Have a Solid Tumor
After pediatric Hodgkin lymphoma, the subsequent risk for a solid tumor goes on and on -- to 40 years and beyond.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma
Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers
(Wiley) New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially high risk. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help refine guidelines for cancer screening in Hodgkin lymphoma survivors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2018 Category: Cancer & Oncology Source Type: news

Medical News Today: What to know about stage 4 lymphoma
The symptoms, treatment, and survival rates of stage 4 lymphoma depend on the type of lymphoma and the risk factors that the individual has. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2018 Category: Consumer Health News Tags: Lymphoma Source Type: news

Nordstrom co-president Blake Nordstrom diagnosed with lymphoma
Blake Nordstrom said he will undergo chemotherapy over the next few months in Seattle. Doctors have told him he can continue to work throughout this process. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 10, 2018 Category: Health Management Authors: Coral Garnick Source Type: news

Nordstrom co-president Blake Nordstrom diagnosed with lymphoma
Blake Nordstrom said he will undergo chemotherapy over the next few months in Seattle. Doctors have told him he can continue to work throughout this process. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 10, 2018 Category: Biotechnology Authors: Coral Garnick Source Type: news

ASH Poster Rounds: Adding BTK Inhibitor Safe in First-Line MCL
(MedPage Today) -- Plus: Lenalidomide upfront in PTCL; skipping RT in primary mediastinal B-cell lymphoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2018 Category: Hematology Source Type: news

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III  MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news

Another Rituximab Biosimilar Passes Lymphoma Test
(MedPage Today) -- Noninferior to EU-licensed agent in randomized trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news

Gene Signature Identifies New Subgroup of DLBCL
A new study has identified a clinically and biologically distinct subgroup of diffuse large B-cell lymphoma tumors. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

ASH: A + CHP Bests CHOP for Peripheral T - Cell Lymphoma
Median progression - free survival improved with A + CHP vs CHOP; similar incidence of adverse events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: Does HIV increase cancer risk?
HIV can weaken a person ’s immune system, which can increase the risk of certain types of cancer. Such cancers include Kaposi’s sarcoma, non-Hodgkin lymphoma, and cervical, lung, anal, and oral cancer. However, effective treatment can significantly reduce the risk of developing these cancers. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news

Using Clonal Hematopoiesis to Assess Risk in Lymphoma Patients
Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
MONDAY, Dec. 3, 2018 -- For heavily pretreated patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), response rates are high for treatment subsequent to checkpoint blockade therapy (CBT), according to two... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52 percent of those patients responded favorably to the therapy. Forty percent had a complete response and 12 percent had a partial response. (Source: World Pharma News)
Source: World Pharma News - December 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading: MRI shows promise for lung cancer screening FDG-PET/CT fails for peripheral T-cell lymphoma outcomes FDG-PET/CT helps stage men with breast cancer, too PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Investor Update)
Source: Roche Investor Update - December 3, 2018 Category: Pharmaceuticals Source Type: news

Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

New tool to find and fight most dangerous types of lymphoma
(University of Leeds) UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Combination immunotherapy shows high activity against recurrent Hodgkin lymphoma
(NYU Langone Health / NYU School of Medicine) A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

High-cost Gilead cell therapy proves durable for some lymphoma patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

At two years, Gilead lymphoma therapy active in 40 percent of patients
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial
(University of Texas M. D. Anderson Cancer Center) A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
(Dana-Farber Cancer Institute) New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

New two-year data show 39 percent of NHL patients treated with CAR T remain in remission
(H. Lee Moffitt Cancer Center& Research Institute) A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta ® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
(University of Chicago Medical Center) An international phase-2 trial of a CAR-T cell therapy--to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)--found that 52 percent of patients responded favorably to the therapy; 40 percent had a complete response and 12 percent had a partial response. One year later, 65 percent percent of those patients were relapse-free, including 79 percent of complete responders. The median progression-free survival 'has not been reached.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
(University of Pennsylvania School of Medicine) In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah ® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news